ASND - Ascendis Pharma A/S

QQQ $ 476.41 $ 1.04 (0.22 %)

DIA $ 416.44 $ 1.60 (0.38 %)

SPY $ 563.57 $ 2.80 (0.5 %)

TLT $ 96.64 $ -1.03 (-1.05 %)

GLD $ 231.30 $ -1.09 (-0.47 %)

Previous Close

$ 137.94

Open

$ 138.05

Bid

$ 138.54 x 100

Ask

-- x --

Day's Range

$ 137.60 - $ 138.99

52 Week Range

$ 85.29 - $ 161.00

Volume

265,492

Average Volume

Market Cap

7.96B

Beta (5Y Monthly)

$ 0.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Maintains Overweight on Ascendis...
08/21/2024 14:03:48

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $17...

Jefferies Maintains Buy on Ascendis Pharma...
08/13/2024 17:27:00

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $174 to $196.

loar-holdings-posts-upbeat-results-joins-nvidia-clean-energy-fuels-penumbra-and-other-big-stocks-moving-higher-on-tuesday

Loar Holdings Posts Upbeat Results, Joins ...
08/13/2024 15:44:24

Goldman Sachs Maintains Buy on Ascendis Ph...
08/13/2024 13:27:14

Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $170 to ...

ascendis-hypoparathyroidism-drug-scores-fda-approval-as-first-and-only-treatment-replacing-takedas-drug-discontinued-due-to-supply-issues

Ascendis' Hypoparathyroidism Drug Scores F...
08/12/2024 14:42:45

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous...

Market-Moving News for August 12th
08/12/2024 12:21:29

KEY: 24% | Scotiabank Acquires 14.9% Stake in KeyCorp With $2.8B Strategic Investment ASND: 11% | Ascendia Pharma shares are tr...

Trading Halt: Halt status updated at 7:25:...
08/12/2024 11:25:06

FDA Approves Ascendis Pharma's Yorvipath (...
08/12/2024 11:04:59

Trading Halt: Halted at 6:55:00 a.m. ET - ...
08/12/2024 10:55:03

100-invested-in-this-stock-10-years-ago-would-be-worth-5900-today

$100 Invested In This Stock 10 Years Ago W...
08/09/2024 16:30:44

1000-invested-in-ascendis-pharma-10-years-ago-would-be-worth-this-much-today

$1000 Invested In Ascendis Pharma 10 Years...
07/18/2024 17:00:29

macys-ascendis-pharma-and-3-stocks-to-watch-heading-into-friday

Macy's, Ascendis Pharma And 3 Stocks To Wa...
07/05/2024 08:24:34

U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment ch...

Reported Thursday, Pendopharm Partners Wit...
07/05/2024 06:05:27

Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypo...

heres-how-much-1000-invested-in-ascendis-pharma-15-years-ago-would-be-worth-today

Here's How Much $1000 Invested In Ascendis...
07/03/2024 14:30:16

heres-how-much-you-would-have-made-owning-ascendis-pharma-stock-in-the-last-15-years

Here's How Much You Would Have Made Owning...
06/26/2024 15:02:29

TD Cowen Upgrades Ascendis Pharma to Buy, ...
06/25/2024 11:35:59

TD Cowen analyst Yaron Werber upgrades Ascendis Pharma (NASDAQ:ASND) from Hold to Buy and raises the price target from $156 ...

Ascendis Reports Presentation Of Data From...
06/24/2024 20:48:01

The data showed that patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in w...

Ascendis Pharma To Present New Data And Up...
06/03/2024 20:05:41

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...

if-you-invested-100-in-this-stock-15-years-ago-you-would-have-4100-today

If You Invested $100 In This Stock 15 Year...
05/31/2024 20:30:22

Stifel Initiates Coverage On Ascendis Phar...
05/31/2024 10:03:41

Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...